Adlai Nortye Revenue

Pharmaceutical Manufacturing • Gongshu District, Zhejiang, China • 51-100 Employees

Adlai Nortye revenue & valuation

Annual revenue	$24,904,000,000
Revenue per employee	$401,678,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$79,692,800,000
Total funding	$40,000,000

Key Contacts at Adlai Nortye

Audrey Xue

Associate Director Human Resources

Tianyi Yuan

Associate Director, Business Development

Xuyang Song

Executive Director, Global Head Of Clinical Pharmacology & Dmpk

Robert Atkinson

Associate Director, Global Clinical Operations

Ian Oldham

Senior Director, Regulatory Operations

俊周

Ir&Pr Director

Company overview

Headquarters	Gongshu District, Zhejiang, China
Phone number	+864338399
Website	adlainortye.com
NAICS	3254
SIC	873
Keywords	生物医药 And 制药
Founded	2016
Employees	51-100
Socials

Adlai Nortye Email Formats

Adlai Nortye uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@adlainortye.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@adlainortye.com	66.7%
{first name}.{last name}	john.doe@adlainortye.com	33.3%

About Adlai Nortye

阿诺医药（纳斯达克股票代码：ANL）是一家临床阶段的全球性生物制药公司，在中美两地均设有研发及临床运营中心，通过“联合创新”和“自主研发”的模式构建起多条全球化的产品管线，其中：AN2025（buparlisib）取得 FDA的快速通道资格，其与紫杉醇联用期望可成为治疗PD-1失败后的二线复发性或转移性HNSCC的首款药物，正在开展全球多中心的III期临床试验；AN0025（palupiprant）是一款期望通过调节肿瘤微环境治疗实体瘤的EP4拮抗剂，目前正处于与 Keytruda® 联合治疗多发实体瘤患者的Ib临床试验阶段以及与化放疗联用治疗局部晚期癌症的临床II期研究；AN4005是自主研发的口服小分子PD-L1抑制剂，目前I期临床试验在中美两地同时展开，以确定安全性、耐受性和推荐的2期剂量（RP2D）。此外，阿诺医药还在进行AN2025（PI3K抑制剂）、AN0025（EP4拮抗剂）以及罗氏的抗-PD-L1抗体（Tecentriq）三联疗法用于治疗PI3KCA突变的实体瘤患者的研发，以及一系列临床前试验，包括多功能 T细胞/APC 调节剂AN8025, β-catenin降解剂AN1025以及泛KRAS抑制剂AN9025。阿诺医药已组建了一支经验丰富的管理团队，并搭建了专有的药物研发平台，同时与多家全球领先的制药企业建立了战略合作关系。阿诺医药致力于成为打造“全球新”肿瘤药物的创新型研发企业，为中国乃至全球患者带来更有效的治疗方案，实现将癌症变成一种慢性疾病乃至可治愈疾病的使命。

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Director

Employees by Department

Adlai Nortye has 17 employees across 6 departments.

Departments

Number of employees

Funding Data

Explore Adlai Nortye's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-10-29	14	$40,000,000

Funding Insights

$40,000,000

Total funding amount

$40,000,000

Most recent funding amount

Number of funding rounds

Adlai Nortye Tech Stack

Discover the technologies and tools that power Adlai Nortye's digital infrastructure, from frameworks to analytics platforms.

jQuery

JavaScript libraries

Nginx

Reverse proxies

PHP

Programming languages

HSTS

Security

Swiper

JavaScript libraries

Microsoft 365

Frequently asked questions

Adlai Nortye is located in Gongshu District, Zhejiang, CN.

You can reach Adlai Nortye at +864338399.

Adlai Nortye generates an estimated annual revenue of $24,904,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Adlai Nortye has an estimated valuation of $79,692,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Adlai Nortye was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

Adlai Nortye has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Adlai Nortye has raised a total of $40,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.